siliconindia | | MARCH 20224Education Vol 10 · Issue 03 - 01 · March, 2022 Publisher Alok Chaturvedi Editor Emmanuel Christi Das Editorial Team Aveek Pal Chaudhuri Hima P M Mandvi Singh GM - Sales & Marketing Rohit Kumar Advertising Managers Editorial queries editor@siliconindia.com To subscribe Visit https://www.siliconindia.com/subscribe/ or send email to subscription@siliconindia.com Cover price is Rs.150 per issue. Printed and Published By Alok Chaturvedi on behalf of Siliconmedia Technologies Pvt. Ltd. and Printed at Precision Fototype Services at Sri Sabari Shopping Complex, 24 Residency Road Bangalore-560025 and Published At No. 124, 2nd Floor, Surya Chambers, Old Airport Road, Murugeshpalya, Bangalore-560017. Editor Alok ChaturvediCopyright © 2022 Siliconmedia Technologies Pvt. Ltd., All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher.advertise@siliconindia.com Visualisers Souvik AcharyaGroup Art DirectorAshok KumarCirculation Manager Magendran Perumal Ashwini D Naik Shilpa Selva Felisha Rita Correspondent Soumya JAssistant Editor Ananth VAssociate Editor Indranil Chakraborty siliconindiaEducationClinical trials industry has seen a phenomenal increase in last ten years or so, and India has emerged as one of the foremost global destinations for clinical trials. There is a huge volume of literature available from across the world and from within the country that has commented on the phenomenal growth of the clinical trials industry, especially in the developing world. Clinical research is all set to become the next big thing in India. A large population with a substantial workforce and cost benefits influence multinationals to set up research facilities here. Besides due to the prevalence of a large variety of diseases, including widespread cases of cancer and diabetes India is viewed the world over as the ideal location for clinical research trials for the pharmaceutical industry.Clinical research is one of the mainstay parts of the drug discovery process that is carried out to ensure the efficacy and safety of the drug. Availability of study subjects, highly skilled healthcare professionals, cost effectiveness and timeliness are prerequisites of a successful clinical trial. Large patient pool is one of the reasons that put India up as one of the most favorable destinations for clinical trials. India constitutes about 18% of total world population with one fifth of the global burden of disease. It records highest toll on maternal, neonatal and child deaths in the world.Another important factor that draws the attention of clinical trials industry towards India is cost competitiveness. The cost for conducting clinical trials in India is one tenth of the cost in the USA. With many pharmaceutical companies relocating or outsourcing the clinical trial processes to India, the research and development expenditure in pharmaceutical industry has witnessed an exponential increase. With this increase, the home grown companies offering clinical research have started to match pace with global standards. Today, India's pharmaceutical market witness faster time-to-market. The time is ripe to expand and such firms have realized the same. Do let us know what you think.Emmanuel Christi DasEditoreditor@siliconindia.comMainstay of Drug DiscoveryEditorial
< Page 3 | Page 5 >